Signos, Inc. is a Palo Alto-based healthtech company that offers the first and only FDA-cleared over-the-counter continuous glucose monitoring (CGM) system designed for weight management, combining Dexcom's Stelo biosensor with an AI-driven mobile platform. The system delivers personalized metabolic insights — covering food, activity, sleep, and stress — to help users manage weight and improve metabolic health without a prescription.
“Signos, the company behind the first FDA-cleared, over-the-counter glucose monitoring system for weight management, announced a $20 million funding.”
“Signos, the company behind the first FDA-cleared, over-the-counter glucose monitoring system for weight management.”
“FDA clearance for OTC use is a meaningful regulatory moat that competitors would need to replicate — not just a product distinction.”
AI-extracted from podcast / newsletter / paper summaries. May contain errors.